Humacyte (HUMA) EBITDA (2020 - 2026)
Humacyte (HUMA) posted quarterly EBITDA of -$28.9 million for Q1 2026, down 24.57% year-over-year from -$38.3 million in Q1 2025, and up 6.28% quarter-over-quarter from -$30.8 million in Q4 2025.
Humacyte (HUMA) EBITDA (2020 - 2026) Analysis & Trends
Humacyte (HUMA) has reported EBITDA for 7 consecutive years, with -$28.9 million the latest figure, recorded in Q1 2026.
- In Q1 2026, EBITDA fell 24.57% year-over-year to -$28.9 million; the TTM figure through Mar 2026 stood at -$113.9 million (down 2.55% YoY), while the FY2025 annual figure was -$108.1 million, up 5.47% from the prior year.
- EBITDA rose to -$28.9 million in Q1 2026 per HUMA's latest filing, from -$30.8 million in the prior quarter.
- Across five years, EBITDA topped out at -$18.5 million in Q2 2022 and bottomed at -$30.8 million in Q4 2025.
- Historically, EBITDA has averaged -$25.7 million across 5 years, with a median of -$26.1 million in 2023.
- Annual changes were most pronounced in 2023 — EBITDA slumped 44.25% — and 2025, when it climbed 19.33%.
- Humacyte's EBITDA stood at -$20.8 million in 2022, then declined by 25.65% to -$26.1 million in 2023, then slipped by 7.47% to -$28.1 million in 2024, then fell by 9.79% to -$30.8 million in 2025, then increased by 6.28% to -$28.9 million in 2026.
- Business Quant data shows HUMA's EBITDA at -$28.9 million in Q1 2026, -$30.8 million in Q4 2025, and -$24.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 493.00 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -815.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 325.05 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 231.44 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -1.55 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 133.12 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -375.75 Mn |
| 10 | Humacyte | 158.12 Mn | 158.12 Mn | -825,000.00 | -27.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -27.00 Mn |
| Mar 31, 2026 | -28.90 Mn |
| Dec 31, 2025 | -30.84 Mn |
| Sep 30, 2025 | -24.39 Mn |
| Jun 30, 2025 | -29.73 Mn |
| Mar 31, 2025 | -23.20 Mn |
| Dec 31, 2024 | -28.09 Mn |
| Sep 30, 2024 | -30.23 Mn |
| Jun 30, 2024 | -29.50 Mn |
| Mar 31, 2024 | -26.60 Mn |
| Dec 31, 2023 | -26.14 Mn |
| Sep 30, 2023 | -24.62 Mn |
| Jun 30, 2023 | -26.73 Mn |
| Mar 31, 2023 | -22.50 Mn |
| Dec 31, 2022 | -20.80 Mn |
| Sep 30, 2022 | -23.49 Mn |
| Jun 30, 2022 | -18.53 Mn |
| Mar 31, 2022 | -21.80 Mn |
| Dec 31, 2021 | -21.62 Mn |
| Sep 30, 2021 | -20.54 Mn |